# A Trial to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous TRV250

> **NCT04201080** · PHASE1 · TERMINATED · sponsor: **Trevena Inc.** · enrollment: 9 (actual)

## Conditions studied

- Migraines

## Interventions

- **DRUG:** Part A: TRV250-20mg/ml
- **DRUG:** Placebo
- **DRUG:** Part B: TRV250 Dose 1
- **DRUG:** Part B: TRV250 Dose 2
- **DRUG:** Part B: TRV250 Dose 3
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04201080
- **Lead sponsor:** Trevena Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-11-11
- **Primary completion:** 2020-02-17
- **Final completion:** 2020-08-10
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Because there have been significant enrollment struggles which has been exacerbated by the COVID impact. This has caused an undue delay to the study timelines and its enrollment goals beyond the business needs.
- **Last updated:** 2021-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04201080

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04201080, "A Trial to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous TRV250". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04201080. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*